Allergan can do better than Valeant offer, investor says | MassDevice.com On Call

Valeant Pharmaceuticals' $47 billion offer for aesthetics maker Allergan is nothing to get excited about, says top-20 shareholder Polen Capital Management.

Valeant Pharmaceuticals, Allergan Inc.

News Well, On Call, Cosmetic/Aesthetic, Mergers & Acquisitions

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/RSds9U